Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.
Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin GR. Kakkilaya A, et al. Among authors: al hadidi s. Oncologist. 2024 Sep 5:oyae219. doi: 10.1093/oncolo/oyae219. Online ahead of print. Oncologist. 2024. PMID: 39236068 Free article.
Gender disparities in multiple myeloma publications.
Dweik A, Dweik H, Mian H, Mohan M, Schinke C, Al Hadidi S. Dweik A, et al. Among authors: al hadidi s. EJHaem. 2022 Jun 15;3(3):966-969. doi: 10.1002/jha2.470. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051049 Free PMC article.
Perspectives on the Treatment of Multiple Myeloma.
Rafae A, van Rhee F, Al Hadidi S. Rafae A, et al. Among authors: al hadidi s. Oncologist. 2024 Mar 4;29(3):200-212. doi: 10.1093/oncolo/oyad306. Oncologist. 2024. PMID: 37995307 Free PMC article. Review.
Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review.
Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S. Alrawabdeh J, et al. Among authors: al hadidi s. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad100. doi: 10.1093/jncics/pkad100. JNCI Cancer Spectr. 2023. PMID: 38006333 Free PMC article.
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R. Mohan M, et al. Among authors: al hadidi s. Blood Cancer J. 2024 Mar 5;14(1):35. doi: 10.1038/s41408-024-01003-z. Blood Cancer J. 2024. PMID: 38443345 Free PMC article.
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.
Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M. Akhtar OS, et al. Among authors: al hadidi s. Br J Haematol. 2024 Nov;205(5):1830-1834. doi: 10.1111/bjh.19700. Epub 2024 Aug 27. Br J Haematol. 2024. PMID: 39192546
124 results